Sangui Biotech International (Sangui Biotech International) Beneish M-Score

: 0.00 (As of Today)

View and export this data going back to . Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Sangui Biotech International's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Sangui Biotech International was 0.00. The lowest was 0.00. And the median was 0.00.

Sangui Biotech International Beneish M-Score Historical Data

The historical data trend for Sangui Biotech International's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Beneish M-Score

-2.96

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Beneish M-Score																-3.01	-	-	-	-

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangui Biotech International Beneish M-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Beneish M-Score falls into.

Sangui Biotech International Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sangui Biotech International for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Mar23) TTM:

Last Year (Mar22) TTM:

Total Receivables was $0.03 Mil.
Revenue was 0.019 + 0.011 + 0.041 + 0.011 = $0.08 Mil.
Gross Profit was 0.019 + 0.011 + 0.041 + 0.011 = $0.08 Mil.
Total Current Assets was $0.04 Mil.
Total Assets was $0.09 Mil.
Property, Plant and Equipment(Net PPE) was $0.05 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.05 Mil.
Selling, General, & Admin. Expense(SGA) was $0.19 Mil.
Total Current Liabilities was $1.03 Mil.
Long-Term Debt & Capital Lease Obligation was $0.07 Mil.
Net Income was -0.038 + -0.102 + 0.023 + -0.007 = $-0.12 Mil.
Non Operating Income was -0.01 + -0.071 + 0.046 + 0.043 = $0.01 Mil.
Cash Flow from Operations was 0 + 0.005 + -0.026 + -0.037 = $-0.06 Mil.

Total Receivables was $0.03 Mil.
Revenue was 0.018 + 0.022 + 0.019 + 0.014 = $0.07 Mil.
Gross Profit was 0.018 + 0.022 + 0.019 + 0.014 = $0.07 Mil.
Total Current Assets was $0.12 Mil.
Total Assets was $0.19 Mil.
Property, Plant and Equipment(Net PPE) was $0.07 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.02 Mil.
Selling, General, & Admin. Expense(SGA) was $0.20 Mil.
Total Current Liabilities was $0.98 Mil.
Long-Term Debt & Capital Lease Obligation was $0.10 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0.028 / 0.082)	/	(0.03 / 0.073)
	=	0.341463	/	0.410959
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0.073 / 0.073)	/	(0.082 / 0.082)
	=	1	/	1
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (0.039 + 0.05) / 0.089)	/	(1 - (0.115 + 0.072) / 0.187)
	=	0	/	0
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0.082	/	0.073
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.023 / (0.023 + 0.072))	/	(0.049 / (0.049 + 0.05))
	=	0.242105	/	0.494949
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(0.188 / 0.082)	/	(0.195 / 0.073)
	=	2.292683	/	2.671233
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.072 + 1.027) / 0.089)	/	((0.102 + 0.976) / 0.187)
	=	12.348315	/	5.764706
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-0.124 - 0.008	-	-0.058)	/	0.089
	=	-0.831461

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sangui Biotech International Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines